EyePoint Pharmaceuticals (NASDAQ:EYPT) Earns “Overweight” Rating from Cantor Fitzgerald
EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports. A number of other brokerages also recently commented on EYPT. StockNews.com downgraded shares of EyePoint Pharmaceuticals from a “hold” rating to a “sell” […]
More Stories
Hyundai Warns Owners to Park Outside in Recall of Nearly 95,000 Sedans
By Bill Pan Hyundai is recalling 94,622 sedans nationwide and warning owners to park outdoors, away from buildings and other...
US Considering Use of ‘Mother of All Bombs’ Against Iran
By Jack Phillips U.S. President Donald Trump on Thursday said his administration would not use nuclear weapons against Iran, following...
How to Enhance Video Quality for YouTube Beginners
YouTube has no shortage of great ideas. What separates one channel from another is often how those ideas look on...
DOJ Sues California After Flagging 20,000 ‘Likely Noncitizens’ Registered to Vote
By Jill McLaughlin The Department of Justice (DOJ) filed a lawsuit against California on Oct. 15 over its voter list...
Ukraine Resumes Strikes on Russian Refineries as Zelenskyy Says ‘We’re Done’ With Trump’s Energy Truce
By Guy Birchall Ukraine has resumed attacks on Russian refineries after Ukrainian President Volodymyr Zelenskyy said Kyiv was “done” complying...
Musk Says US Government Is Controlling Starshield Services Amid Reported Disruptions in Ukraine
By Ryan Morgan SpaceX CEO Elon Musk denied reports that the company curbed its military-oriented Starshield satellite internet service in...